Italia markets closed

Dow Jones
39.846,55
+288,44(+0,73%)
Nasdaq
16.732,68
+221,50(+1,34%)
Nikkei 225
38.385,73
+29,67(+0,08%)
EUR/USD
1,0881
+0,0060(+0,55%)
Bitcoin EUR
59.763,16
+3.496,51(+6,21%)
CMC Crypto 200
1.373,46
+105,51(+8,32%)

NVCR Jun 2024 17.500 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,3200

-0,2200

(-40,74%)

In data: 01:50PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in